Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

ClinicalTrials.gov ID: NCT00315276

Public ClinicalTrials.gov record NCT00315276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 9-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With Attention Deficit/Hyperactivity Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate the efficacy and safety of modafinil administered once daily for 9 weeks at doses of 255, 340, 425, and 510 mg as treatment for adults with ADHD.

Study identification

NCT ID: NCT00315276
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Cephalon; Industry
Enrollment: 370 participants

Conditions and interventions

Conditions

Interventions

Modafinil Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2006 (Type not available)
Primary completion: Not listed
Completion: Jan 2007 (Actual)
Last update posted: Aug 24, 2012

2006 – 2007

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
Neurology Clinical Study Centers, LLC	Little Rock	Arkansas	72205	—
Bay Area Research Institute	Lafayette	California	94549	—
Pharmacology Research Institute	Northridge	California	91324	—
Peninsula Research Associates	Rolling Hills Estates	California	90274	—
UCSD Medical Center	San Diego	California	92103	—
Clinical Neuroscience Solution, Inc.	Orlando	Florida	32806	—
University of Illinois	Chicago	Illinois	60608	—
Michael J. Reiser, MD, LLC	Lexington	Kentucky	40509	—
Adult ADD Center of Maryland	Lutherville	Maryland	21093	—
Massachusetts General Hospital	Cambridge	Massachusetts	02138	—
Rochester Center for Behavioral Medicine	Rochester	Michigan	48307	—
CRI WorldWide, LLC	Clementon	New Jersey	08021	—
New York University	New York	New York	10010	—
Summit Research Network Inc.	Portland	Oregon	97210	—
CRI WorldWide, LLC	Philadelphia	Pennsylvania	19149	—
South East Health Consultants, LLC	Charleston	South Carolina	29407	—
Clinical Neuroscience Solution	Memphis	Tennessee	38119	—
Neuropsychiatric Associates	Woodstock	Vermont	05091	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00315276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2012 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00315276 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →